|52Wk High:||52Wk Low:|
iBio Inc., a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBioLaunch platform. The iBioLaunch platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies and other therapeutic proteins and vaccines. Instead of materials such as chicken eggs, mammalian and insect cells, transgenic plants and human blood plasma required by other systems, iBioLaunch uses proprietary, transient gene expression in unmodified green plants to produce important biologic pharmaceuticals. This unique, plant-based platform offers a number of significant advantages over other systems.